



US005889052A

United States Patent [19]

Klimko et al.

[11] Patent Number: 5,889,052

[45] Date of Patent: *Mar. 30, 1999

[54] USE OF CLOPROSTENOL AND FLUPROSTENOL ANALOGUES TO TREAT GLAUCOMA AND OCULAR HYPERTENSION

[75] Inventors: Peter G. Klimko, Fort Worth, Tex.; John E. Bishop, Groton, Mass.; Verney L. Sallee, Burleson; Paul W. Zinke, Fort Worth, both of Tex.

[73] Assignee: Alcon Laboratories, Inc., Fort Worth, Tex.

[*] Notice: The term of this patent shall not extend beyond the expiration date of Pat. Nos. 5,510,383, and 5,665,773.

[21] Appl. No.: 917,795

[22] Filed: Aug. 21, 1997

Related U.S. Application Data

[63] Continuation of Ser. No. 769,293, Dec. 18, 1996, Pat. No. 5,665,773, which is a continuation of Ser. No. 280,681, Jul. 26, 1994, abandoned, which is a continuation-in-part of Ser. No. 101,598, Aug. 3, 1993, Pat. No. 5,510,383.

[51] Int. Cl.⁶ A61K 31/557

[52] U.S. Cl. 514/530; 514/573

[58] Field of Search 514/530, 573

References Cited

U.S. PATENT DOCUMENTS

3,954,881	5/1976	Bowler	568/645
4,159,343	6/1979	Skuballa et al.	514/548
4,256,745	3/1981	Skuballa et al.	514/239.2
4,321,275	3/1982	Bowler et al.	514/570
4,599,353	7/1986	Bito et al.	514/570
5,173,507	12/1992	DeSantis et al.	514/530
5,288,754	2/1994	Woodward et al.	514/530
5,352,708	10/1994	Woodward et al.	514/729
5,480,900	1/1996	DeSantis et al.	514/392
5,510,383	4/1996	Bishop et al.	514/530
5,565,492	10/1996	DeSantis et al.	514/530
5,605,922	2/1997	DeSantis et al.	514/392
5,665,773	9/1997	Klimko et al.	514/530

FOREIGN PATENT DOCUMENTS

308 135 A2	3/1989	European Pat. Off.	.
330 511 A2	8/1989	European Pat. Off.	.
364 417 A1	4/1990	European Pat. Off.	.
366 279 A2	5/1990	European Pat. Off.	.
435 682 A2	7/1991	European Pat. Off.	.

603 800 A1	6/1994	European Pat. Off.	.
1350971	4/1974	United Kingdom	.
14686832	9/1977	United Kingdom	.
1553710	10/1979	United Kingdom	.
90/02553	3/1990	WIPO	.
94/06433	3/1994	WIPO	.
94/08585	4/1994	WIPO	.

OTHER PUBLICATIONS

Bito et al., "The Ocular Effects of Prostaglandins and the Therapeutic Potential of New PGF₂α Analog, PhXA41 (latanoprost), for Glaucoma Management," *J. of Lipid Mediators*, 6:535-543 (1993).

Burke et al., "Prostaglandin F₂α Effects on Rabbit IOP Negatively Correlate With Classical PGF₂α Receptor Stimulation" ARVO, Sarasota, Florida, vol. 29, p. 325, May 1-6, 1988.

Coleman et al., "Prostanoids and their Receptors," *Comprehensive Medicinal Chemistry*, vol. 3, 12.11:643-714.

Narumiya et al., "Structure and Function of Prostanoid Receptors," *J. of Lipid Mediators*, 6:155-161 (1993).

Resul et al., "Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents," *J. Med. Chem.*, 36:243-248 (1993).

Stjernschantz et al., "Phenyl Substituted Prostaglandin Analogs for Glaucoma Treatment," *Drugs of the Future*, 17(8):691-704 (1992).

The Merck Index, 11th Ed., p. 375 (1989).

The Merck Index, 11th Ed., pp. 656-657 (1989).

Woodward et al., "Definition of Prostanoid Receptor Subtypes by Radioligand Binding and the Effects of Selective Agonists on Intraocular Pressure" *Ex. Eye Res.* 55(1):s91 (1992).

Woodward et al., "Intraocular Pressure Effects of Selective Prostanoid Receptor Agonists Involve Different Receptor Subtypes According to Radioligand Binding Studies," *J. of Lipid Mediators*, 6:545-553 (1993).

Zajacz et al., "Effect on Human Eye of Prostaglandin and a Prostaglandin Analogue Used to Induce Abortion," *IRCS Medical Science: Clinical Medicine: Clinical Pharmacology & Therapeutics: Drug Metabolism & Toxicology: The Eye: Reproduction, Obstetrics & Gynecology*, 4:316 (1976).

Primary Examiner—Richard L. Raymond
Attorney, Agent, or Firm—Barry L. Copeland

ABSTRACT

Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.

22 Claims, No Drawings